Nanjing Leads Biolabs Co., Ltd. Class H (9887) Stock Statistics & Valuation Metrics

Nanjing Leads Biolabs Co., Ltd. Class H has a market cap or net worth of HK$14.33B. The enterprise value is HK$8.66K.

Nanjing Leads Biolabs Co., Ltd. Class H has 197,670,290 shares outstanding. The number of shares has decreased by -2.65% in one year.

Nanjing Leads Biolabs Co., Ltd. Class H’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -14.00%.

The current PE Ratio of Nanjing Leads Biolabs Co., Ltd. Class H is ―. Nanjing Leads Biolabs Co., Ltd. Class H’s PEG ratio is -0.09.

In the last 12 months, Nanjing Leads Biolabs Co., Ltd. Class H had revenue of 197.20M and earned -235.21M in profits. Earnings per share was -1.35.

In the last 12 months, operating cash flow was -26.36M and capital expenditures -384.00K, giving a free cash flow of -26.75M billion.

Nanjing Leads Biolabs Co., Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Nanjing Leads Biolabs Co., Ltd. Class H upcoming earnings date is Aug 31, 2026, Before Open (Confirmed).

Nanjing Leads Biolabs Co., Ltd. Class H as a current ratio of 3.37, with Debt / Equity ratio of 22.16%

In the past 12 months, Nanjing Leads Biolabs Co., Ltd. Class H has paid 17.27M in taxes.

Nanjing Leads Biolabs Co., Ltd. Class H EV to EBITDA ratio is -35.36, with an EV/FCF ratio of -42.69.

Nanjing Leads Biolabs Co., Ltd. Class H has HK$1.72B in cash and marketable securities with HK$312.13M in debt, giving a net cash position of HK$1.41B billion.

Gross margin is 100.00%, with operating margin of -109.75%, and net profit margin of -119.27%.

The average price target for Nanjing Leads Biolabs Co., Ltd. Class H is HK$98.63, which is 11.43% higher than the current price. The consensus rating is Moderate Buy